Department of Infectious Diseases, ASST Fatebenefratelli Sacco, "L. Sacco" University Hospital, Via Giovanni Battista Grassi N. 74, 20157, Milan, Italy.
Department of Medicine, Mayo Clinic, Division of Public Health, Infectious Diseases and Occupational Medicine, 200 1St St SW, Rochester, MN, 55905, USA.
Neurol Sci. 2024 Nov;45(11):5441-5448. doi: 10.1007/s10072-024-07621-6. Epub 2024 Jun 11.
Neurobrucellosis presents diverse clinical challenges and risks of long-term complications.
We aimed to assess the relationship between the duration of antibiotic therapy, clinical factors, and the outcome of neurobrucellosis with a case report combined with a systematic review of the literature.
We present a case of a 31 years-old man successfully treated at our Institution. We then searched Ovid MEDLINE, Embase and Scopus for articles that encompassed neurobrucellosis cases, duration of treatment, and outcome. The primary outcome was to assess an association between the duration of treatment and the risk of sequelae or relapses. Univariate, multivariate and sensitivity analysis were carried out to define which variables affected the clinical outcome. Quality assessment was performed using a dedicated tool.
A total of 123 studies were included, totaling 221 patients. Median duration of treatment was 4 months (IQR 3 - 6), 69% patients recovered without sequelae, 27% had sequelae. Additionally, five patients had a relapse, and 4 patients died. Multivariate analysis found that the duration of treatment, age, and the use of ceftriaxone were not associated with a higher risk of sequelae or relapses. A significant association was found for corticosteroids use (OR 0.39, 95% IC 0.16 - 0.96, p = 0.038), motor impairment (OR 0.29, 95% IC 0.14 - 0.62, p = 0.002), and hearing loss (OR 0.037, 95% IC 0.01 - 0.11, p < 0.001).
This study highlights the variability in clinical presentations and treatment approaches for neurobrucellosis. Patients with factors indicating higher sequelae risk require meticulous follow-up.
神经型布氏杆菌病呈现出多样化的临床挑战和长期并发症风险。
我们旨在评估抗生素治疗持续时间、临床因素与神经型布氏杆菌病结局之间的关系,为此结合病例报告与文献系统综述进行研究。
我们报道了 1 例在本机构成功治疗的 31 岁男性患者。随后,我们在 Ovid MEDLINE、Embase 和 Scopus 中检索了包含神经型布氏杆菌病病例、治疗持续时间和结局的文章。主要结局是评估治疗持续时间与后遗症或复发风险之间的关联。我们进行了单变量、多变量和敏感性分析,以确定哪些变量影响了临床结局。使用专用工具进行了质量评估。
共纳入了 123 项研究,共计 221 例患者。治疗持续时间的中位数为 4 个月(IQR 3-6),69%的患者无后遗症恢复,27%的患者有后遗症。此外,有 5 例患者复发,4 例患者死亡。多变量分析发现,治疗持续时间、年龄和使用头孢曲松与后遗症或复发风险增加无关。使用皮质类固醇与后遗症或复发风险显著相关(OR 0.39,95%CI 0.16-0.96,p=0.038),运动障碍与后遗症或复发风险显著相关(OR 0.29,95%CI 0.14-0.62,p=0.002),听力损失与后遗症或复发风险显著相关(OR 0.037,95%CI 0.01-0.11,p<0.001)。
本研究强调了神经型布氏杆菌病临床表现和治疗方法的多样性。具有较高后遗症风险因素的患者需要进行细致的随访。